 Sean Davis
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Software | 2 | 2016 | 692 | 0.580 |
Why?
| | Genomics | 4 | 2016 | 836 | 0.420 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2016 | 550 | 0.320 |
Why?
| | Sarcoma, Synovial | 1 | 2007 | 20 | 0.260 |
Why?
| | Neoplasms | 4 | 2016 | 2884 | 0.260 |
Why?
| | DNA Copy Number Variations | 3 | 2016 | 183 | 0.240 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2007 | 211 | 0.220 |
Why?
| | Exome | 3 | 2016 | 227 | 0.210 |
Why?
| | Disease Models, Animal | 3 | 2017 | 4569 | 0.150 |
Why?
| | MicroRNAs | 2 | 2016 | 701 | 0.140 |
Why?
| | Point Mutation | 2 | 2016 | 243 | 0.130 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.130 |
Why?
| | Exons | 2 | 2016 | 358 | 0.130 |
Why?
| | Receptors, Glucocorticoid | 2 | 2009 | 138 | 0.130 |
Why?
| | Enhancer Elements, Genetic | 2 | 2015 | 192 | 0.120 |
Why?
| | Adenomatous Polyps | 1 | 2016 | 9 | 0.120 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2016 | 20 | 0.120 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2017 | 119 | 0.120 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2016 | 40 | 0.120 |
Why?
| | NFI Transcription Factors | 1 | 2015 | 8 | 0.110 |
Why?
| | Genetic Variation | 3 | 2015 | 984 | 0.110 |
Why?
| | Comparative Genomic Hybridization | 1 | 2015 | 28 | 0.110 |
Why?
| | Protein-Lysine 6-Oxidase | 1 | 2014 | 14 | 0.110 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3550 | 0.110 |
Why?
| | Osteosarcoma | 1 | 2015 | 76 | 0.110 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2014 | 36 | 0.110 |
Why?
| | Stomach Neoplasms | 1 | 2016 | 128 | 0.110 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2017 | 276 | 0.110 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2015 | 99 | 0.100 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2015 | 131 | 0.100 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2013 | 11 | 0.100 |
Why?
| | Leukemia, Hairy Cell | 1 | 2013 | 7 | 0.100 |
Why?
| | Neoplasms, Second Primary | 1 | 2015 | 100 | 0.100 |
Why?
| | Mutation Rate | 1 | 2013 | 30 | 0.100 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2013 | 71 | 0.100 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 85 | 0.100 |
Why?
| | Interferon Regulatory Factors | 1 | 2013 | 44 | 0.100 |
Why?
| | Data Mining | 1 | 2014 | 117 | 0.100 |
Why?
| | Transcription Factors | 3 | 2017 | 1742 | 0.100 |
Why?
| | DNA Methylation | 2 | 2016 | 683 | 0.100 |
Why?
| | Databases, Nucleic Acid | 1 | 2013 | 39 | 0.100 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2013 | 191 | 0.090 |
Why?
| | Esophageal Neoplasms | 1 | 2017 | 349 | 0.090 |
Why?
| | Bone Neoplasms | 1 | 2015 | 256 | 0.090 |
Why?
| | Thyroid Hormone Receptors beta | 1 | 2012 | 1 | 0.090 |
Why?
| | Chromosomes, Human, X | 1 | 2012 | 76 | 0.090 |
Why?
| | RNA, Messenger | 3 | 2016 | 2832 | 0.090 |
Why?
| | Genome | 1 | 2014 | 306 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 642 | 0.090 |
Why?
| | DNA, Neoplasm | 1 | 2012 | 164 | 0.090 |
Why?
| | Replication Origin | 1 | 2011 | 21 | 0.090 |
Why?
| | Pituitary Gland | 1 | 2012 | 148 | 0.090 |
Why?
| | Osteoblasts | 1 | 2012 | 145 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2017 | 1126 | 0.080 |
Why?
| | Genetic Loci | 1 | 2012 | 261 | 0.080 |
Why?
| | Thyroid Neoplasms | 1 | 2014 | 346 | 0.080 |
Why?
| | Gene Silencing | 1 | 2011 | 205 | 0.080 |
Why?
| | Osteogenesis | 1 | 2012 | 208 | 0.080 |
Why?
| | Wnt Signaling Pathway | 1 | 2012 | 210 | 0.080 |
Why?
| | Genetic Linkage | 3 | 2016 | 273 | 0.080 |
Why?
| | beta Catenin | 1 | 2012 | 253 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2015 | 2147 | 0.080 |
Why?
| | DNA Replication | 1 | 2011 | 251 | 0.070 |
Why?
| | Computational Biology | 1 | 2014 | 681 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 1462 | 0.070 |
Why?
| | Genome, Human | 1 | 2011 | 422 | 0.070 |
Why?
| | Breast Neoplasms | 2 | 2015 | 2456 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2016 | 931 | 0.070 |
Why?
| | Transcription, Genetic | 2 | 2015 | 1496 | 0.070 |
Why?
| | Response Elements | 1 | 2009 | 89 | 0.070 |
Why?
| | Gene Expression Regulation | 4 | 2015 | 2609 | 0.070 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 1407 | 0.070 |
Why?
| | Chromatin | 2 | 2011 | 561 | 0.070 |
Why?
| | Myoblasts, Skeletal | 1 | 2007 | 12 | 0.060 |
Why?
| | Muscular Diseases | 1 | 2007 | 108 | 0.060 |
Why?
| | Animals | 10 | 2017 | 38109 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2015 | 1169 | 0.060 |
Why?
| | Mice | 8 | 2017 | 18365 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2008 | 675 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 978 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2015 | 2050 | 0.050 |
Why?
| | Mutation | 2 | 2013 | 4099 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2642 | 0.050 |
Why?
| | Humans | 15 | 2017 | 144957 | 0.050 |
Why?
| | Nuclear Proteins | 3 | 2013 | 749 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1786 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 3 | 2015 | 2365 | 0.040 |
Why?
| | Recombination, Genetic | 2 | 2012 | 205 | 0.040 |
Why?
| | Base Sequence | 2 | 2014 | 2191 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 965 | 0.040 |
Why?
| | ErbB Receptors | 2 | 2017 | 629 | 0.040 |
Why?
| | Apoptosis | 1 | 2008 | 2430 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2013 | 531 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2017 | 194 | 0.030 |
Why?
| | Candidiasis | 1 | 2017 | 64 | 0.030 |
Why?
| | Cellular Reprogramming | 1 | 2017 | 103 | 0.030 |
Why?
| | Mice, SCID | 1 | 2017 | 369 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1796 | 0.030 |
Why?
| | Allelic Imbalance | 1 | 2016 | 9 | 0.030 |
Why?
| | Teratoma | 1 | 2017 | 120 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2009 | 758 | 0.030 |
Why?
| | Gastric Mucosa | 1 | 2016 | 52 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2016 | 52 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2017 | 610 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2015 | 36 | 0.030 |
Why?
| | Mutagenesis, Insertional | 1 | 2015 | 64 | 0.030 |
Why?
| | Janus Kinase 3 | 1 | 2015 | 19 | 0.030 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2015 | 55 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2017 | 229 | 0.030 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2015 | 15 | 0.030 |
Why?
| | DNA-Binding Proteins | 2 | 2013 | 1500 | 0.030 |
Why?
| | p300-CBP Transcription Factors | 1 | 2015 | 26 | 0.030 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2015 | 42 | 0.030 |
Why?
| | Pedigree | 1 | 2016 | 514 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 322 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2015 | 247 | 0.030 |
Why?
| | Gene Amplification | 1 | 2015 | 121 | 0.030 |
Why?
| | DNA Transposable Elements | 1 | 2015 | 122 | 0.030 |
Why?
| | Heterografts | 1 | 2014 | 144 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2017 | 437 | 0.030 |
Why?
| | Splicing Factor U2AF | 1 | 2013 | 18 | 0.030 |
Why?
| | Connectin | 1 | 2013 | 42 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 336 | 0.030 |
Why?
| | Immunoglobulin Variable Region | 1 | 2013 | 80 | 0.030 |
Why?
| | Pyrroles | 1 | 2015 | 218 | 0.020 |
Why?
| | Transcription Factor AP-2 | 1 | 2013 | 82 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2015 | 124 | 0.020 |
Why?
| | Melanocytes | 1 | 2013 | 65 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2015 | 373 | 0.020 |
Why?
| | Pigmentation | 1 | 2013 | 53 | 0.020 |
Why?
| | Piperidines | 1 | 2015 | 217 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 509 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2015 | 374 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 688 | 0.020 |
Why?
| | Cell Lineage | 1 | 2015 | 376 | 0.020 |
Why?
| | Ribonucleoproteins | 1 | 2013 | 103 | 0.020 |
Why?
| | Segmental Duplications, Genomic | 1 | 2012 | 8 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 695 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 685 | 0.020 |
Why?
| | Transfection | 1 | 2014 | 940 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2014 | 2197 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 627 | 0.020 |
Why?
| | Alleles | 1 | 2015 | 881 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2012 | 54 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2013 | 173 | 0.020 |
Why?
| | Fanconi Anemia | 1 | 2011 | 11 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 299 | 0.020 |
Why?
| | Chromosomal Instability | 1 | 2011 | 21 | 0.020 |
Why?
| | Checkpoint Kinase 2 | 1 | 2011 | 27 | 0.020 |
Why?
| | Protein Stability | 1 | 2012 | 178 | 0.020 |
Why?
| | K562 Cells | 1 | 2011 | 93 | 0.020 |
Why?
| | Transcription Initiation Site | 1 | 2011 | 43 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2011 | 69 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1258 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 824 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 409 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2012 | 510 | 0.020 |
Why?
| | Prostate | 1 | 2012 | 158 | 0.020 |
Why?
| | Pyrimidines | 1 | 2015 | 533 | 0.020 |
Why?
| | CpG Islands | 1 | 2011 | 165 | 0.020 |
Why?
| | Autoimmunity | 1 | 2017 | 927 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1129 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3125 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1835 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4155 | 0.020 |
Why?
| | Autoantigens | 1 | 2012 | 429 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2931 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 528 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 321 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 139 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2012 | 592 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 430 | 0.020 |
Why?
| | Female | 5 | 2016 | 78376 | 0.020 |
Why?
| | Databases, Factual | 1 | 2014 | 1486 | 0.020 |
Why?
| | Tyrphostins | 1 | 2008 | 18 | 0.020 |
Why?
| | Genes, erbB-2 | 1 | 2008 | 33 | 0.020 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 31 | 0.020 |
Why?
| | Nucleoproteins | 1 | 2008 | 38 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2499 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 2012 | 579 | 0.020 |
Why?
| | Family | 1 | 2012 | 679 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2011 | 629 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2008 | 132 | 0.020 |
Why?
| | Mesoderm | 1 | 2008 | 150 | 0.020 |
Why?
| | Epithelium | 1 | 2008 | 314 | 0.020 |
Why?
| | Phosphorylation | 1 | 2011 | 1733 | 0.020 |
Why?
| | Disease Progression | 1 | 2014 | 2852 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2009 | 383 | 0.020 |
Why?
| | DNA Helicases | 1 | 2008 | 143 | 0.020 |
Why?
| | Quinazolines | 1 | 2008 | 266 | 0.020 |
Why?
| | RNA Interference | 1 | 2008 | 476 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2008 | 356 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1054 | 0.010 |
Why?
| | RNA Polymerase II | 1 | 2009 | 351 | 0.010 |
Why?
| | Kinetics | 1 | 2009 | 1629 | 0.010 |
Why?
| | Receptors, Estrogen | 1 | 2008 | 457 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 444 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2008 | 381 | 0.010 |
Why?
| | Proteomics | 1 | 2011 | 1195 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 5997 | 0.010 |
Why?
| | Histones | 1 | 2008 | 670 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2882 | 0.010 |
Why?
| | Protein Binding | 1 | 2008 | 2276 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 970 | 0.010 |
Why?
| | RNA | 1 | 2008 | 940 | 0.010 |
Why?
| | Signal Transduction | 1 | 2013 | 5233 | 0.010 |
Why?
| | Phenotype | 1 | 2008 | 3164 | 0.010 |
Why?
| | Young Adult | 1 | 2015 | 14126 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 7183 | 0.010 |
Why?
| | Male | 2 | 2016 | 72406 | 0.010 |
Why?
| | Middle Aged | 1 | 2015 | 35928 | 0.010 |
Why?
| | Adult | 1 | 2015 | 40506 | 0.010 |
Why?
|
|
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|